Return to the catalog
Ipamorelin
PopularIn Stock5mg vial

Ipamorelin

Selective peptide studied for growth-hormone release with limited effects on other hormones.

For Research Use Only

Sold strictly for laboratory research. Not for human or veterinary use, ingestion, or clinical/diagnostic application.

1–4 vialsR 500.00
5+ vials — save 30%R 350.00 each

The lower price is applied automatically once your cart holds 5 or more of this vial.

Bacteriostatic water included

99%+ Purity
Extensively Researched
1

About this peptide

Ipamorelin is a small peptide that activates the ghrelin receptor, a signal involved in growth-hormone release. It is studied because research models show a more selective growth-hormone response, with less effect on hormones such as cortisol and prolactin. Researchers examine its effects on hormone patterns, recovery, and body composition.

Why researchers reach for Ipamorelin

Selective GH release

Minimal impact on cortisol and prolactin in preclinical data.

Short pulsatile profile

Half-life supports pulse-mimicking protocols.

Pairs with GHRH analogues

Standard comparator with CJC-1295 in research.

Key features

  • ≥99% HPLC purity
  • Pentapeptide ghrelin-receptor agonist
  • Mass-spec verified
  • Cold-chain dispatch

How it works

GHS-R1a agonism

Selectively activates the ghrelin receptor on somatotrophs.

GH pulse induction

Triggers a short, physiologic GH pulse.

Clean profile

Does not meaningfully engage ACTH or prolactin pathways.

Research dosage guidelines

Reference ranges only — reproduced from published preclinical literature. Not a recommendation for human use.

RangeReported doseNote
Typical reconstitution2 mL bacteriostatic waterYields 2.5 mg/mL (2500 mcg/mL)
Reported research range200–300 mcg per doseReference only

Tracking this compound? Registered researchers can log active Ipamorelin protocols in their private Research Log.

Timing in research protocols

Evening or pre-exercise windows in study designs, based on growth-hormone physiology rather than a timing trial.

  • No registered human trial has compared times of day for ipamorelin specifically; the original pharmacology work (Raun et al., 1998) is in swine and rat pituitary models.
  • Secondary pharmacokinetic summaries report a short profile — peak around 15–30 minutes, half-life near 2 hours — which is why study protocols cluster doses rather than spacing them widely.
  • Fasted, low-somatostatin windows such as before sleep are favoured in protocols because food intake, particularly carbohydrate and fat, blunts endogenous growth-hormone pulses.
  • Cycle lengths reported in the literature are not standardised.

Drawn from published research protocols and pharmacology literature. Reference information for laboratory research only — not an instruction or guidance for use.

Technical specifications

Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2
Molecular weight
711.86 g/mol
Purity
≥99% (HPLC)
Form
Lyophilized powder
Vial size
5 mg
Storage (lyophilised vial)
Cool, dry and protected from light
Storage (after reconstitution)
2–8°C

Published research

Peer-reviewed literature on Ipamorelin. Links open in a new tab.

Research use notice

Sold for in vitro laboratory research only. Not for human or veterinary use, diagnosis, or therapy.

#ghrelin#growth-hormone#selective

Cart (0)

Your cart is empty